{"id":"W2995889981","doi":"10.1016/j.jtho.2019.12.109","title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":438,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Merck Sharp and Dohme; EMD Serono; Genentech; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; National Cancer Institute; Servier; Daiichi-Sankyo; Puma Biotechnology; AbbVie; Aminex Therapeutics; Roche; Celgene; Novartis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003534099,0.0005812052,0.001764596,0.000446559,0.0004385334,0.001304475,0.0005699467,0.00114965,0.001559717],"category_scores_gemma":[0.003258924,0.0003058845,0.003167236,0.0008270339,0.0004065018,0.001301843,0.0005777788,0.002209684,0.0002729253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00123456,"about_ca_system_score_gemma":0.001301173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003719497,"about_ca_topic_score_gemma":0.008082888,"domain_scores_codex":[0.9988469,0.0004750684,0.0001066586,0.0001895095,0.0001854301,0.0001964736],"domain_scores_gemma":[0.9979951,0.0006247172,0.0006262257,0.0001512645,0.0001806277,0.0004220728],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5616761,0.009536147,0.1532152,0.004873816,0.02064393,0.000419543,0.000410772,0.001264061,0.004846759,0.0003045983,0.004892764,0.2379163],"study_design_scores_gemma":[0.2037579,0.1386792,0.6025093,0.002033627,0.03191094,0.0008208581,0.0005526109,0.000678161,0.002309015,0.0003718022,0.01623529,0.0001413597],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9530311,0.04082446,0.000158502,0.0007433758,0.0002069237,0.0003686854,0.001712364,0.00001306526,0.002941652],"genre_scores_gemma":[0.9799722,0.01439768,0.0003730914,0.001114055,0.0003168823,0.0002889189,0.00242807,0.000009562576,0.001099469],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003719497,"threshold_uncertainty_score":0.01869029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05916321030402624,"score_gpt":0.4761060156971092,"score_spread":0.416942805393083,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}